Immunogenicity risk assessment of synthetic peptide drugs and their impurities by Elena Iemma | Jul 27, 2023Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements by Riley Nolan | Oct 11, 2022
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS by Annie De Groot | Oct 30, 2018EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release
